Escala Medical has successfully raised $4.5 million in Series A funding.
This investment was partly funded by the European Innovation Council (EIC) Fund, after Escala received a €2.5 million grant from their Accelerator program in October 2023. The funding round also included private investors from the United States and Israel.
With this new funding, Escala has now raised more than $8 million in total. The company is also supported by The Trendlines Group, UK-based Consensus Business Group (CBG), and other private investors.
“This funding marks an important milestone as we continue to scale our operations and bring our breakthrough technology to more women worldwide,” stated Dr. Edit Goldberg, CEO of Escala. “We’re proud to have the support of the EIB and our private investors, and we remain committed to advancing the next generation of our Mendit device to improve outcomes and expand access to millions of women worldwide who suffer from organ prolapse.
Escala creates new repair solutions for women with Pelvic Organ Prolapse (POP). Their main product, Mendit, made together with Trendlines, has been used successfully in more than 500 surgeries.
The company was founded in 2014 by pelvic surgeons Dr. Roger Goldberg and Professor Douglas Scherr, who, as Edit Goldberg explained to CTech, “recognized a significant gap in the treatment of pelvic organ prolapse (POP) for women who are either ineligible for surgery, are unhappy with supportive therapies, or are unwilling to undergo an invasive surgical procedure.”
Goldberg noted that while nearly 50% of women over age 40 experience POP, only 10% undergo surgery due to the risks and recovery.
“The device offers a minimally invasive, office-based alternative to traditional surgery, combining surgical-grade effectiveness with unmatched versatility,” she continued.
“As the first truly minimally invasive, reversible anchor-based system, Mendit opens the door to treatment for the 90% of women who currently go without care.”
Goldberg says the market for Pelvic Organ Prolapse (POP) treatment is worth over $7 billion worldwide. Every year, more than 8 million women in the U.S. and Europe look for treatment. The main customers are hospitals, surgery centers, and private clinics. Doctors who do these procedures include gynecologists, urogynecologists, and urologists.
Other companies offer treatments using tools like suture passers and anchor systems (such as EnPlace, AnchorSure, and Saffron), but these need cuts and surgery rooms. Goldberg explains that Mendit is different because it can repair POP without any cuts, is reversible, and can be done in a doctor’s office.
In the U.S., Mendit got approval from the FDA in April 2023 and started selling in October 2023. It is already approved in 48 hospitals, including some big health systems, with many more hospitals close to approving it.
In Israel, Mendit is approved by the Ministry of Health, and it is expected to get CE mark approval for Europe in 2026.
Goldberg told the media that the money from this funding round will be used to grow the business in the U.S. They will also enter the European market once they get CE approval and expand into Southeast Asia with help from a new partner in Singapore. The funds will also be used to improve the product and run clinical studies after the product is on the market.
“Being selected for the EIC Accelerator and receiving both a grant and equity investment from the EIC Fund is a major vote of confidence in our technology, our team, and our vision,” added Robert D. Auerbach, M.D., Chair of Escala.
Svetoslava Georgieva, Chair of the EIC Fund Board, said the EIC’s support of Escala “marks a significant milestone in their journey to bring much-needed innovation to women’s health.”
Read more- Hudle Secures $2.5 Million in Series A Funding Led by Sky Impact Capital
